Ascendis Pharma A/S (NASDAQ:ASND) Given Sell (D-) Rating at Weiss Ratings

Key Points

• Ascendis Pharma A/S has been given a sell (D-) rating by Weiss Ratings, while other analysts have issued various positive ratings and targets for the stock.
• The company reported a quarterly earnings of ($0.93) earnings per share, surpassing analysts' expectations and generating revenues of $216.28 million.
• Ascendis Pharma's stock has fluctuated between a 12-month low of $118.03 and a high of $216.45, with current trading around $202.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s stock had its "sell (d-)" rating reaffirmed by research analysts at Weiss Ratings in a research note issued on Friday,Weiss Ratings reports.

Several other equities research analysts have also recently commented on ASND. Royal Bank Of Canada increased their price target on Ascendis Pharma A/S from $210.00 to $230.00 and gave the company an "outperform" rating in a report on Friday, August 8th. Cowen restated a "buy" rating on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Citigroup reiterated a "buy" rating and issued a $290.00 target price (up from $243.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. UBS Group reiterated a "buy" rating and issued a $307.00 target price (up from $306.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Finally, Cantor Fitzgerald raised their price target on Ascendis Pharma A/S from $203.00 to $254.00 and gave the company an "overweight" rating in a research note on Monday, October 13th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $249.80.

Ascendis Pharma A/S Price Performance

ASND stock traded up $0.99 during mid-day trading on Friday, reaching $202.00. 368,820 shares of the company's stock were exchanged, compared to its average volume of 480,389. The company has a market cap of $12.46 billion, a price-to-earnings ratio of -39.15 and a beta of 0.41. The stock's 50 day moving average is $199.85 and its 200 day moving average is $179.01. Ascendis Pharma A/S has a 12-month low of $118.03 and a 12-month high of $216.45.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.42) by $0.49. The business had revenue of $216.28 million for the quarter, compared to analysts' expectations of $163.17 million. On average, research analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors have recently added to or reduced their stakes in ASND. Perceptive Advisors LLC purchased a new stake in Ascendis Pharma A/S in the 2nd quarter valued at approximately $166,367,000. T. Rowe Price Investment Management Inc. lifted its stake in Ascendis Pharma A/S by 12.0% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company's stock valued at $475,970,000 after buying an additional 328,278 shares in the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in Ascendis Pharma A/S in the 1st quarter valued at $51,029,000. RA Capital Management L.P. raised its holdings in Ascendis Pharma A/S by 1.7% in the 1st quarter. RA Capital Management L.P. now owns 10,281,496 shares of the biotechnology company's stock valued at $1,602,474,000 after acquiring an additional 168,752 shares during the last quarter. Finally, Braidwell LP acquired a new position in Ascendis Pharma A/S in the 1st quarter valued at $16,632,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.